Remedy has its sights on bringing to market a system for neurovascular intervention, while Capstan performed the first U.S. transcatheter mitral valve replacement with its investigational robot.
Remedy Robotics, a San Francisco-based startup developing robotic systems for cardiovascular and endovascular treatments, said it raised $62 million in a new funding round.
The financing will support a planned pivotal trial in partnership with the University of California, with the aim of advancing toward Food and Drug Administration approval for neurovascular intervention.
Remedy said it is finalizing development of its N1 system designed for on-site, remote or autonomous operation. The artificial intelligence-enabled robotic platform uses machine learning to analyze preoperative imaging, simulate cases in advance, provide real-time image registration and complete endovascular procedures.
The company believes its system has the potential to expand access to and improve the quality of specialized neurovascular, coronary and peripheral vascular care. Remedy said it now works with more than 100 hospitals worldwide. In October 2025, the company announced it successfully completed remote neurointerventional procedures with the N1 system.
Venture capital firm DCVC led the Series B funding round. New investors included UC Investments, the University of California's investment arm, Skip Capital and Australian pension fund Hostplus.
Capstan Medical said the first U.S. transcatheter mitral valve replacement was performed with its investigational robot.
The procedu re, on Nov. 9 at The Christ Hospital in Cincinnati, was part of an FDA-authorized early feasibility study. The patient was discharged in stable condition, Dr. Santiago Garcia, director of the hospital’s structural heart program, said in a statement.
Source link







